公开(公告)号：US09394363B2

公开(公告)日：2016-07-19

申请号：US13685899

申请日：2012-11-27

Applicant: ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

Inventor： Jijie Gu ,  Chung-Ming Hsieh ,  Zhen Wu ,  Enrico L. DiGiammarino ,  Feng Luo ,  Gerard B. Fox ,  John E. Harlan ,  Martin Schmidt ,  Ralf Loebbert ,  Reinhold Mueller ,  Ulrich Ebert ,  Volker Nimmrich

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12P21/005 ,  Y02A50/466

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.

Abstract translation: 本申请涉及分离的蛋白质，特别是单克隆抗体，特别是结合RAGE蛋白质的CDR-移植的人源化抗体。 具体地说，这些抗体具有抑制RAGE与其各种配体结合的能力。 本申请中描述的抗体或其部分可用于治疗由RAGE的病理生理学配体表征或诱导的疾病或病症，例如错折叠蛋白如淀粉样蛋白和bgr; 和晚期糖基化终产物。

公开(公告)号：US20140227294A1

公开(公告)日：2014-08-14

申请号：US14138906

申请日：2013-12-23

Applicant: ABBVIE INC.

Inventor： Mark Anderson ,  Jieyi Wang ,  Archana Thakur ,  Debra Chao ,  Chung-Ming Hsieh ,  Qian Zhang ,  Edward B. Reilly ,  Enrico L. DiGiammarino ,  Kenton L. Longenecker ,  Russell A. Judge ,  David A. Egan ,  Charles W. Hutchins

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2869 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/466

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract translation: 本发明包括PRLR结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hPRLR具有高亲和力，并在体外和体内中和hPRLR活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hPRLR和抑制hPRLR活性，例如在患有hPRLR活性有害的病症的人类受试者中。 本发明还包括抗PRLR抗体药物偶联物（ADC）。